EMEA-001045-PIP01-10-M02
Key facts
| Invented name |
Kevzara
|
| Active substance |
sarilumab
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0114/2021
|
| PIP number |
EMEA-001045-PIP01-10-M02
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Sanofi-Aventis Recherche & Développement
Tel. +33 169745695 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|